Prothena - PRTA Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRTA shares.
View PRTA analyst ratings or view top-rated stocks.

8 brokerages have issued 1-year price targets for Prothena's shares. Their PRTA share price forecasts range from $55.00 to $120.00. On average, they anticipate the company's stock price to reach $82.50 in the next twelve months. This suggests a possible upside of 67.3% from the stock's current price.
View analysts price targets for PRTA or view top-rated stocks among Wall Street analysts.

Prothena's stock was trading at $60.25 on January 1st, 2023. Since then, PRTA shares have decreased by 18.2% and is now trading at $49.30.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our PRTA earnings forecast.

Prothena Co. plc (NASDAQ:PRTA) announced its quarterly earnings results on Thursday, February, 23rd. The biotechnology company reported $0.12 earnings per share for the quarter, topping analysts' consensus estimates of ($0.64) by $0.76. The biotechnology company had revenue of $49.90 million for the quarter, compared to analysts' expectations of $29.14 million. Prothena had a negative net margin of 216.95% and a negative trailing twelve-month return on equity of 24.98%. The company's revenue was up 4058.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.71) earnings per share.

ETFs with the largest weight of Prothena (NASDAQ:PRTA) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and Invesco DWA SmallCap Momentum ETF (DWAS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

Prothena's stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (6.63%), Avidity Partners Management LP (6.10%), First Light Asset Management LLC (3.17%), Dimensional Fund Advisors LP (2.73%), T. Rowe Price Investment Management Inc. (1.92%) and Geode Capital Management LLC (1.48%). Insiders that own company stock include Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Karin L Walker, Lars Ekman, Michael J Malecek, Michael J Malecek, Richard T Collier, Shane Cooke, Tran Nguyen and Wagner M Zago.
View institutional ownership trends.

Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PRTA stock can currently be purchased for approximately $49.30.

Prothena (NASDAQ:PRTA) has a market capitalization of $2.59 billion and generates $53.90 million in revenue each year. The biotechnology company earns $-116,950,000.00 in net income (profit) each year or ($2.51) on an earnings per share basis.

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The official website for the company is www.prothena.com. The biotechnology company can be reached via phone at (531) 236-2500, via email at ellen.rose@prothena.com, or via fax at 353-1902-3510.